MedTrace Logo

Elimination of Hepatitis C Virus Among Users of Substances

NCT05503979 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2022-09-29

No results posted yet for this study

Summary

Substance users are a vulnerable group that should be prioritized in HCV (Hepatitis C Virus) elimination efforts in Mexico and in which it is feasible to carry out micro-elimination programs. It is an important group to treat both because of its high prevalence and because of the dynamic spread of infection among the general population. HCV seropositivity has not been documented in this group of people in Mexico City, the metropolitan area and the northern states of the country, nor has the sustained viral response been evaluated in this group of patients in the Mexican population.

Conditions

  • Hepatitis C in Substance Users

Interventions

DRUG

Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa]

1 tab every 24 hrs for 12 weeks

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

    lead OTHER

Principal Investigators

  • Graciela Castro-Narro, MD · INCMNSZ

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-15
Primary Completion
2023-08-15
Completion
2024-05-15
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05503979 on ClinicalTrials.gov